Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rcAd26.MOS1.HIV-Env oral vaccine for HIV-1
NCT02366013Phase 1Completed
- Sponsor
- International AIDS Vaccine Initiative
- Start
- Jan 2015
- Primary completion
- Jun 2016
- Modality
- Viral Vectors, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of rcAd26.MOS1.HIV-Env in human immunodeficiency virus infection (HIV), sponsored by International AIDS Vaccine Initiative. Started Jan 2015; status: completed.
02
Drugs
rcAd26.MOS1.HIV-Env
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02366013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02366013.